Antibody Clinical Trials In-Vivo RNA 
Drug Discovery World
MAY 17, 2024
The top stories: Gene therapy cures profound genetic deafness within 24 weeks The investigational gene therapy DB-OTO improved hearing to normal levels in a child (dosed at 11 months of age) within 24 weeks, according to trial data presented at the American Society of Gene and Cell Therapy (ASGCT) annual conference.
WCG Clinical
MAY 28, 2024
Recent headlines have highlighted the potential for Chimeric Antigen Receptor (CAR)-based therapies to provide clinical benefits to persons affected by lupus. Recently clinical investigators have found a way to turn what was an undesirable side effect in cancer patients into a clinical benefit for persons with certain autoimmune conditions.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
JULY 15, 2024
Additionally, Ariceum Therapeutics’ Head of Translational Biology & Non-Clinical Pharmacology, Anika Jäkel, also described the conference agenda as “truly diverse,” which covered “many forms of therapeutic approaches, with some revelatory findings about new biomarkers that could lead to a new generation of personalised therapies.”
XTalks
APRIL 22, 2022
Flow cytometric receptor occupancy assays are being increasingly used in preclinical and clinical studies. Both the areas of drug development and clinical trials are increasingly using in vitro assays to help determine the efficacy of an investigational therapeutic. What is Flow Cytometry?
The Pharma Data
DECEMBER 10, 2020
The goal of targeting both S and N was to both activate virus-specific T cells and generate anti-SARS-CoV-2-neutralizing antibodies. The vaccine targeted both the inner nucleocapsid (N) and the outer spike (S) proteins of the virus to maximize the immune response. This can significantly limit the effectiveness of first-generation platforms.
Drug Discovery World
SEPTEMBER 6, 2022
And whilst clinical trials activity decreased by around 15% compared to 2020, last year still saw a number of regenerative medicines reach the bedside. Last year saw the sector surge, with levels of investment hitting an all-time high at $22.7 billion, compared to $19.9 billion, compared to $19.9 million price point per dose.
Drug Discovery World
NOVEMBER 30, 2023
The company’s goal is to accelerate functional characterisation and shortenoptimisation time in antibody discovery and t-cell workflows. DDW’s Megan Thomas attended PEGS Europe 2023 in Lisbon, Portugal, from Tuesday 14 November to Thursday 16 November 2023. GSK has developed high-throughput mammalian and E.
Expert insights. Personalized for you.
52 
Let's personalize your content